Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
Identifieur interne : 001502 ( Ncbi/Curation ); précédent : 001501; suivant : 001503Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
Auteurs : Werner Poewe [Autriche] ; Erik Wolters ; Murat Emre ; Marco Onofrj ; Chuanchieh Hsu ; Sibel Tekin ; Roger LaneSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- Activities of Daily Living, Aged, Cholinesterase Inhibitors (therapeutic use), Cognition (physiology), Dementia (complications), Dementia (drug therapy), Double-Blind Method, Female, Humans, Longitudinal Studies, Male, Neuropsychological Tests (statistics & numerical data), Parkinson Disease (complications), Parkinson Disease (drug therapy), Phenylcarbamates (therapeutic use), Time Factors, Treatment Outcome.
- MESH :
- chemical , therapeutic use : Cholinesterase Inhibitors, Phenylcarbamates.
- complications : Dementia, Parkinson Disease.
- drug therapy : Dementia, Parkinson Disease.
- physiology : Cognition.
- statistics & numerical data : Neuropsychological Tests.
- Activities of Daily Living, Aged, Double-Blind Method, Female, Humans, Longitudinal Studies, Male, Time Factors, Treatment Outcome.
Abstract
In patients with dementia associated with Parkinson's disease (PD), the efficacy and safety of rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, were previously demonstrated in a 24-week double-blind placebo-controlled trial. Our objective was to determine whether benefits were sustained over the long term. Following the double-blind trial, all patients were permitted to enter an active treatment extension study, during which they received rivastigmine 3-12 mg/day. Standard safety assessments were performed. Efficacy assessments included the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog) and other measures of cognition, daily function, neuropsychiatric symptoms, and executive function. Of 433 patients who completed the double-blind trial, 334 entered and 273 completed the active treatment extension. At 48 weeks, the mean ADAS-cog score for the whole group improved by 2 points above baseline. Placebo patients switching to rivastigmine for the active treatment extension experienced a mean cognitive improvement similar to that of the original rivastigmine group during the double-blind trial. The adverse event profile was comparable to that seen in the double-blind trial. Long-term rivastigmine treatment appeared well tolerated and may provide sustained benefits in dementia associated with PD patients who remain on treatment for up to 48 weeks.
DOI: 10.1002/mds.20700
PubMed: 16229010
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002E27
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002E27
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002C46
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001502
Links to Exploration step
pubmed:16229010Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.</title><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><nlm:affiliation>Innsbruck Medical University, Innsbruck, Austria. werner.poewe@uibk.ac.at</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Innsbruck Medical University, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Wolters, Erik" sort="Wolters, Erik" uniqKey="Wolters E" first="Erik" last="Wolters">Erik Wolters</name></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name></author><author><name sortKey="Onofrj, Marco" sort="Onofrj, Marco" uniqKey="Onofrj M" first="Marco" last="Onofrj">Marco Onofrj</name></author><author><name sortKey="Hsu, Chuanchieh" sort="Hsu, Chuanchieh" uniqKey="Hsu C" first="Chuanchieh" last="Hsu">Chuanchieh Hsu</name></author><author><name sortKey="Tekin, Sibel" sort="Tekin, Sibel" uniqKey="Tekin S" first="Sibel" last="Tekin">Sibel Tekin</name></author><author><name sortKey="Lane, Roger" sort="Lane, Roger" uniqKey="Lane R" first="Roger" last="Lane">Roger Lane</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="doi">10.1002/mds.20700</idno><idno type="RBID">pubmed:16229010</idno><idno type="pmid">16229010</idno><idno type="wicri:Area/PubMed/Corpus">002E27</idno><idno type="wicri:Area/PubMed/Curation">002E27</idno><idno type="wicri:Area/PubMed/Checkpoint">002C46</idno><idno type="wicri:Area/Ncbi/Merge">001502</idno><idno type="wicri:Area/Ncbi/Curation">001502</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.</title><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><nlm:affiliation>Innsbruck Medical University, Innsbruck, Austria. werner.poewe@uibk.ac.at</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Innsbruck Medical University, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Wolters, Erik" sort="Wolters, Erik" uniqKey="Wolters E" first="Erik" last="Wolters">Erik Wolters</name></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name></author><author><name sortKey="Onofrj, Marco" sort="Onofrj, Marco" uniqKey="Onofrj M" first="Marco" last="Onofrj">Marco Onofrj</name></author><author><name sortKey="Hsu, Chuanchieh" sort="Hsu, Chuanchieh" uniqKey="Hsu C" first="Chuanchieh" last="Hsu">Chuanchieh Hsu</name></author><author><name sortKey="Tekin, Sibel" sort="Tekin, Sibel" uniqKey="Tekin S" first="Sibel" last="Tekin">Sibel Tekin</name></author><author><name sortKey="Lane, Roger" sort="Lane, Roger" uniqKey="Lane R" first="Roger" last="Lane">Roger Lane</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living</term><term>Aged</term><term>Cholinesterase Inhibitors (therapeutic use)</term><term>Cognition (physiology)</term><term>Dementia (complications)</term><term>Dementia (drug therapy)</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Neuropsychological Tests (statistics & numerical data)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Phenylcarbamates (therapeutic use)</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Cholinesterase Inhibitors</term><term>Phenylcarbamates</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Dementia</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dementia</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Cognition</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Neuropsychological Tests</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Activities of Daily Living</term><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Time Factors</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In patients with dementia associated with Parkinson's disease (PD), the efficacy and safety of rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, were previously demonstrated in a 24-week double-blind placebo-controlled trial. Our objective was to determine whether benefits were sustained over the long term. Following the double-blind trial, all patients were permitted to enter an active treatment extension study, during which they received rivastigmine 3-12 mg/day. Standard safety assessments were performed. Efficacy assessments included the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog) and other measures of cognition, daily function, neuropsychiatric symptoms, and executive function. Of 433 patients who completed the double-blind trial, 334 entered and 273 completed the active treatment extension. At 48 weeks, the mean ADAS-cog score for the whole group improved by 2 points above baseline. Placebo patients switching to rivastigmine for the active treatment extension experienced a mean cognitive improvement similar to that of the original rivastigmine group during the double-blind trial. The adverse event profile was comparable to that seen in the double-blind trial. Long-term rivastigmine treatment appeared well tolerated and may provide sustained benefits in dementia associated with PD patients who remain on treatment for up to 48 weeks.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001502 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001502 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:16229010
|texte= Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:16229010" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |